Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer

被引:4
作者
Henderson, Randal H. [1 ]
Bryant, Curtis M. [1 ]
Nichols, R. Charles [1 ]
Mendenhall, William M. [1 ]
Hoppe, Bradford S. [2 ]
Su, Zhong [1 ]
Morris, Christopher G. [1 ]
Mendenhall, Nancy P. [1 ]
机构
[1] Univ Florida, Coll Med, Dept Radiat Oncol, 2015 North Jefferson St, Jacksonville, FL 32206 USA
[2] Mayo Clin, Dept Radiat Oncol, Jacksonville, FL 32224 USA
关键词
Particle therapy; radiation therapy; proton therapy genitourinary; cancer outcomes; radiation oncology; INTENSITY-MODULATED RADIOTHERAPY; 5-YEAR OUTCOMES; RADIATION-THERAPY; TRIAL;
D O I
10.1080/0284186X.2021.2016948
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background To report 5- and 7-year outcomes after image-guided moderately accelerated hypofractionated proton therapy (AHPT) for prostate cancer. Material and methods We reviewed the first 582 prostate cancer patients enrolled on prospective outcomes tracking trial and treated with double-scattered moderately AHPT between 2008 and 2015. 269 patients had low-risk (LR) and 313 had intermediate-risk (IR) disease, including 149 with favorable intermediate-risk (FIR) and 164 with unfavorable intermediate-risk (UIR) disease. LR patients received a median 70.0GyRBE (2.5GyRBE/fraction) and IR patients received a median of 72.5 GyRBE. Seventeen patients (UIR, n = 12) received androgen deprivation therapy (ADT) for a median of 6 months. Toxicities were graded per the CTCAE, v4.0, and patient-reported quality-of-life data were reviewed. Results Median follow-up was 8.0 years (0.9-12.2). The 5- and 7-year rates of freedom from biochemical progression (FFBP) overall and in the LR and IR subsets, respectively, were 96.8/95.2%, 98.8/98.8%, and 95.0/91.9%. For the FIR and UIR subsets, they were 97.2/95.2% and 93.1/88.8%. Actuarial 5- and 7-year rates of late CTCAE, v4.0, grade 2 gastrointestinal (GI), grade 3 GI, and grade 3 genitourinary (GU) toxicities were 9.9%/11.2%, 1.4/1.4% and 1.3/2.1%, respectively. No grade >= 4 GI or GU toxicities occurred. The mean (standard deviation, SD) IPSS and EPIC Composite bowel function and bother scores were 7 (SD = 5), 97 (SD = 7), and 94 (SD = 6), respectively at baseline, 7 (SD = 5), 92 (SD = 13), and 92 (SD = 9) at the 5-year follow-up, and 7 (SD = 5), 93 (SD = 12), and 92 (SD = 10) at the 7-year follow-up. Conclusion Image-guided AHPT 5- and 7-year outcomes show high efficacy, minimal physician-assessed toxicity, and excellent patient-reported outcomes in this cohort.
引用
收藏
页码:468 / 477
页数:10
相关论文
共 19 条
[1]   Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer [J].
Abu-Gheida, Ibrahim ;
Reddy, Chandana A. ;
Kotecha, Rupesh ;
Weller, Michael A. ;
Shah, Chirag ;
Kupelian, Patrick A. ;
Mian, Omar ;
Ciezki, Jay P. ;
Stephans, Kevin L. ;
Tendulkar, Rahul D. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (02) :325-333
[2]   Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer [J].
Bryant, Curtis ;
Smith, Tamara L. ;
Henderson, Randal H. ;
Hoppe, Bradford S. ;
Mendenhall, William M. ;
Nichols, R. Charles ;
Morris, Christopher G. ;
Williams, Christopher R. ;
Su, Zhong ;
Li, Zuofeng ;
Lee, Derek ;
Mendenhall, Nancy P. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 95 (01) :422-434
[3]   Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer [J].
Catton, Charles N. ;
Lukka, Himu ;
Gu, Chu-Shu ;
Martin, Jarad M. ;
Supiot, Stephane ;
Chung, Peter W. M. ;
Bauman, Glenn S. ;
Bahary, Jean-Paul ;
Ahmed, Shahida ;
Cheung, Patrick ;
Tai, Keen Hun ;
Wu, Jackson S. ;
Parliament, Matthew B. ;
Tsakiridis, Theodoros ;
Corbett, Tom B. ;
Tang, Colin ;
Dayes, Ian S. ;
Warde, Padraig ;
Craig, Tim K. ;
Julian, Jim A. ;
Levine, Mark N. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (17) :1884-+
[4]   Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial [J].
Dearnaley, David ;
Syndikus, Isabel ;
Mossop, Helen ;
Khoo, Vincent ;
Birtle, Alison ;
Bloomfield, David ;
Graham, John ;
Kirkbride, Peter ;
Logue, John ;
Malik, Zafar ;
Money-Kyrle, Julian ;
O'Sullivan, Joe M. ;
Panades, Miguel ;
Parker, Chris ;
Patterson, Helen ;
Scrase, Christopher ;
Staffurth, John ;
Stockdale, Andrew ;
Tremlett, Jean ;
Bidmead, Margaret ;
Mayles, Helen ;
Naismith, Olivia ;
South, Chris ;
Gao, Annie ;
Cruickshank, Clare ;
Hassan, Shama ;
Pugh, Julia ;
Griffin, Clare ;
Hall, Emma .
LANCET ONCOLOGY, 2016, 17 (08) :1047-1060
[5]   Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer [J].
Grewal, Amardeep S. ;
Schonewolf, Caitlin ;
Min, Eun Jeong ;
Chao, Hann-Hsiang ;
Both, Stefan ;
Lam, Sarah ;
Mazzoni, Susan ;
Bekelman, Justin ;
Christodouleas, John ;
Vapiwala, Neha .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (04) :713-722
[6]   Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial [J].
Hamstra, Daniel A. ;
Mariados, Neil ;
Sylvester, John ;
Shah, Dhiren ;
Karsh, Lawrence ;
Hudes, Richard ;
Beyer, David ;
Kurtzman, Steven ;
Bogart, Jeffrey ;
Hsi, R. Alex ;
Kos, Michael ;
Ellis, Rodney ;
Logsdon, Mark ;
Zimberg, Shawn ;
Forsythe, Kevin ;
Zhang, Hong ;
Soffen, Edward ;
Francke, Patrick ;
Mantz, Constantine ;
Rossi, Peter ;
DeWeese, Theodore ;
Daignault-Newton, Stephanie ;
Fischer-Valuck, Benjamin W. ;
Chundury, Anupama ;
Gay, Hiram ;
Bosch, Walter ;
Michalski, Jeff .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 97 (05) :976-985
[7]   Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer [J].
Henderson, Randal H. ;
Bryant, Curtis ;
Hoppe, Bradford S. ;
Nichols, R. Charles ;
Mendenhall, William M. ;
Flampouri, Stella ;
Su, Zhong ;
Li, Zuofeng ;
Morris, Christopher G. ;
Mendenhall, Nancy P. .
ACTA ONCOLOGICA, 2017, 56 (07) :963-970
[8]   Comparative Effectiveness Study of Patient-Reported Outcomes After Proton Therapy or Intensity-Modulated Radiotherapy for Prostate Cancer [J].
Hoppe, Bradford S. ;
Michalski, Jeff M. ;
Mendenhall, Nancy P. ;
Morris, Christopher G. ;
Henderson, Randal H. ;
Nichols, Romaine C. ;
Mendenhall, William M. ;
Williams, Christopher R. ;
Regan, Meredith M. ;
Chipman, Jonathan J. ;
Crociani, Catrina M. ;
Sandler, Howard M. ;
Sanda, Martin G. ;
Hamstra, Daniel A. .
CANCER, 2014, 120 (07) :1076-1082
[9]   Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience [J].
Kupelian, Patrick A. ;
Willoughby, Twyla R. ;
Reddy, Chandana A. ;
Klein, Eric A. ;
Mahadevan, Arul .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (05) :1424-1430
[10]   Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer [J].
Lee, W. Robert ;
Dignam, James J. ;
Amin, Mahul B. ;
Bruner, Deborah W. ;
Low, Daniel ;
Swanson, Gregory P. ;
Shah, Amit B. ;
D'Souza, David P. ;
Michalski, Jeff M. ;
Dayes, Ian S. ;
Seaward, Samantha A. ;
Hall, William A. ;
Nguyen, Paul L. ;
Pisansky, Thomas M. ;
Faria, Sergio L. ;
Chen, Yuhchyau ;
Koontz, Bridget F. ;
Paulus, Rebecca ;
Sandler, Howard M. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (20) :2325-U39